Milestone (NASDAQ: MIST) holder to sell 79,500 shares in planned trade

Rhea-AI Filing Summary

A holder of Milestone Pharmaceuticals (MIST) common stock has filed a notice of intent to sell 79,500 shares through broker Morgan Stanley Smith Barney LLC on or around January 8, 2026 on the NASDAQ. The filing lists an aggregate market value of $170,925.00 for this planned sale and notes that 85,169,344 common shares were outstanding.

The securities to be sold were acquired on November 16, 2018 by exercising stock options for cash. The notice also reports that over the past three months there was a separate 10b5-1 sale for Joseph Oliveto of 500 common shares, with gross proceeds of $1,125.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	79500	170925.00	85169344	01/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/16/2018	Previously Exercised Stock Options	Issuer			79500	11/16/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JOSEPH OLIVETO 1111 Dr. Frederik-Philips Blvd,Suite 420 Montreal A8 H4M 2X6	COMMON	01/07/2026	500	1125.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Milestone Pharmaceuticals (MIST) shares are planned to be sold in this Form 144?

The notice states an intent to sell 79,500 shares of common stock through Morgan Stanley Smith Barney LLC on or around January 8, 2026 on the NASDAQ.

What is the reported market value of the MIST shares in this planned Form 144 sale?

The filing lists an aggregate market value of $170,925.00 for the planned sale of 79,500 common shares of Milestone Pharmaceuticals.

When and how were the MIST shares being sold in this Form 144 originally acquired?

The 79,500 common shares were acquired on November 16, 2018 through previously exercised stock options, with the purchase paid in cash on that date.

How many Milestone Pharmaceuticals shares were outstanding according to this notice?

The Form 144 lists 85,169,344 common shares of Milestone Pharmaceuticals as outstanding at the time referenced in the filing.

Were there any other recent sales of MIST shares reported by the same person?

Yes. Over the past three months, the notice reports 10b5-1 sales for Joseph Oliveto of 500 common shares on January 7, 2026, with $1,125.00 in gross proceeds.

What representation does the seller make about inside information in this Form 144?

By signing the notice, the seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.